Stock comparison
Harmony Biosciences Holdings
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HRMY
Harmony Biosciences Holdings
Market cap
$1.75B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HRMY | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 75B | IDXX |
| Benjamin Graham | 60C | 80A | IDXX |
| Philip Fisher | 75B | 75B | Tie |
| Peter Lynch | 62C | 71B | IDXX |
| Joel Greenblatt | 28F | 83C | IDXX |
| Charlie Munger | 62C | 87A | IDXX |
| Terry Smith | 67B | 84A | IDXX |
Side-by-side metrics
| Metric | HRMY | IDXX |
|---|---|---|
| Market cap | $1.75B | $44.12B |
| P/E (TTM) | 11.8x | 39.0x |
| EV/EBIT | 6.4x | 31.6x |
| ROIC (TTM) | 12.5% | 40.66% |
| Gross margin | 76.55% | 62.05% |
| Net margin | 16.2% | 24.63% |
| Revenue CAGR 5y | 29.85% | 7.56% |
| EPS CAGR 5y | 46.45% | 10.79% |
| Debt / Equity | 0.2x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HRMY leads on
- EV/EBIT6.4xvs 31.6x+80%
- EPS CAGR 5y46.45%vs 10.79%+77%
- Revenue CAGR 5y29.85%vs 7.56%+75%
- P/E (TTM)11.8xvs 39.0x+70%
IDXX leads on
- Market cap$44.12Bvs $1.75B+96%
- ROIC (TTM)40.66%vs 12.5%+69%
- Net margin24.63%vs 16.2%+34%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.